Reproducibility of preclinical data: one man's poison is another man's meat
Journal Title: Advances in Precision Medicine - Year 2016, Vol 1, Issue 2
Abstract
Limited reproducibility of preclinical data is increasingly discussed in the literature. Failure of drug development programs due to lack of clinical efficacy is also of growing concern. The two phenomena may share an important root cause — a lack of robustness in preclinical research. Such a lack of robustness can be a relevant cause of failure in translating preclinical findings into clinical efficacy and hence attrition, and exaggerated cost in drug development. Apart from the study design and data analysis factors (e.g., insufficient sample sizes, failure to implement blinding, and randomization), heterogeneity among experimental models (e.g., animal strains) and the conditions of the study used between different laboratories is a major contributor to the lacking of robustness of research findings. The flipside of this coin is that the understanding of the causes of heterogeneity across experimental models may lead to the identification of relevant factors for defining the responder populations. Thus, this heterogeneity within preclinical findings could be an asset, rather than an obstacle, for precision medicine. To enable this paradigm shift, several steps need to be taken to identify conditions under which drugs do not work. An improved granularity in the reporting of preclinical studies is central among them (i.e., details about the study design, experimental conditions, quality of tools and reagents, validation of assay conditions, etc.). These actions need to be discussed jointly by the research communities interested in preclinical data robustness and precision medicine. Thus, we propose that a lack of robustness due to the heterogeneity across models and conditions of the study is not necessarily a liability for biomedical research but can be transformed into an asset of precision medicine.
Authors and Affiliations
Anton Bespalov, Christoph H. Emmerich, Björn Gerlach and Martin C. Michel
Keywords
Related Articles
- EP ID EP679269
- DOI -
- Views 187
- Downloads 0
The role of open innovation in biomarker discovery
Precision medicine aims to treat diseases with special consideration for the individual biological variability. Novel biomarkers (BM) are needed to predict therapeutic responses and to allow for the selection of suitable...
Validation of novel multiplex technologies
Cytokine and chemokine levels in body fluid provide information of altered conditions in patients. The parallel analysis of multiple factors, such as cytokines, from small sample sizes is an interesting approach for the...
Personalized medicine: consequences for drug research and therapy
In drug research, a serious transformation has taken place. With increasing knowledge gained from molecular medicine, it became possible to refine and develop new therapies based on the molecular mechanisms of diseases....
Success factors in drug discovery and development
The article aimed to give a personal perspective on drug discovery and development. The author has worked both in Big Pharma as a scientist and manager and more recently also in start-up biotech companies. Drug companies...
Precision medicine: do not neglect the hurdles
Tremendous expectations have been connected with precision medicine in the past years. Beside the advantages that this type of therapy offers we should be aware of its challenges too. In this issue we will highlight on...